Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 27, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The filing details an increase in the notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan on March 23, 2007. This change resulted from a re-valuation of the cash element of the notional investment held in GSK Ordinary Share ADRs.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Date: March 23, 2007.
- Transaction Price: $54.84 per share.
- Involved Parties: Mrs C Bruck Slaoui and Dr R G Greig.
- Nature of Event: Increase in notional allocation of Ordinary Share ADRs due to plan re-valuation.
- Reporting Date: March 27, 2007.